CURATIS N AG
Research CURATIS N AG (CURN) on Bullrun: market cap CHF 101.75M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCURN
- ExchangeSW
- CountrySwitzerland
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyCHF
- Market capCHF 101.75M
- Financial periodFY2025
- RevenueCHF 10.80M
- Revenue growth56.6%
- Net income-CHF 1.42M
- Free cash flow-CHF 2.53M
- Gross margin26.3%
Valuation Snapshot
latest market cap is CHF 101.75M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CHF 10.80M | -CHF 1.42M | -CHF 2.53M | 26.3% | -0.28 | CHF 1.87M | n/a | CHF 46.08M |
| FY2024 | CHF 6.90M | -CHF 4.35M | -CHF 825.00K | 23.0% | -1.49 | CHF 3.01M | CHF 0 | CHF 45.60M |
| FY2023 | CHF 0 | -CHF 49.38M | -CHF 1.89M | n/a | -176.38 | CHF 9.00K | CHF 133.00K | -CHF 312.00K |
| FY2022 | CHF 0 | -CHF 34.73M | -CHF 4.66M | n/a | -221.63 | CHF 1.34M | CHF 3.00M | CHF 6.75M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-09-26 | CHF 101.75M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 CHF.
About CURATIS N AG
Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases.
Related stock research
Other Healthcare stocks
Galderma Group N (GALD)
PolyPeptide Group AG (PPGN)
Sandoz Group AG (SDZ)
Siegfried Holding Ltd (SFZN)
Ascom Holding AG (0QON)
AC Immune SA (ACIU)
Adc Therapeutics SA (ADCT)
Addex Therapeutics Ltd (ADXN)
Aevis Victoria SA (AEVS)
Alcon Inc (ALC)
Bachem Holding AG (BANB)
BB Biotech AG (BION.SW)
Frequently asked questions
What is CURATIS N AG's market cap?
CURATIS N AG's market capitalization is CHF 101.75M.
What does CURATIS N AG do?
Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases.